| Literature DB >> 29962519 |
Gautier Chene1,2, Sarah Urvoas1, Stéphanie Moret1, Béatrice Nadaud3, Annie Buenerd3, Philippe Chabert1, Georges Mellier1, Gery Lamblin1.
Abstract
INTRODUCTION: The aim of this study is to assess the prevalence of tubal histopathological abnormalities (serous tubal intraepithelial carcinoma STIC and p53 signatures) and the prevalence of perioperative and postoperative complications related to opportunistic laparoscopic salpingectomy in a low risk population.Entities:
Keywords: hysterectomy; laparoscopy; opportunistic salpingectomy; ovarian cancer; p53 signature; prophylactic salpingectomy
Year: 2018 PMID: 29962519 PMCID: PMC6018067 DOI: 10.1055/a-0611-5167
Source DB: PubMed Journal: Geburtshilfe Frauenheilkd ISSN: 0016-5751 Impact factor: 2.915
Table 1 Demographic data, per and postoperative (%). N = 100. The mean age of the population was 49.3 years. The type of laparoscopic hysterectomies was total in 72% and subtotal in 28%. Laparoscopic salpingectomy was always possible without any peri- or postoperative complication attibutable to the salpingectomy itself. The mean duration of salpingectomy was 428 seconds (354 – 596) and the blood loss during salpingectomy was 9 cm 3 (2 – 15).
| Age (years) | 49.3 |
| BMI (kg/m 2) | 26.3 |
| Gestational status | 2.9 |
| Parity | 2.35 |
| Personal or family past history of gynecologic cancer | 0 |
| Type of laparoscopic hysterectomy | 28 subtotal hysterectomies (28%) |
| Preoperative complications during salpingectomy | 0 |
| Postoperative complications attributable to salpingectomy | 0 |
| Postoperative complications attributable to the hysterectomy | 6 (6%) |
bleeding at the right uterine pedicle | 1 (1%) |
ureteral injury | 1 (1%) |
vaginal cuff bleeding | 2 (2%) |
urinary tract infection | 2 (2%) |
| Duration of salpingectomy (seconds) | 428 (354 – 596) |
| Postsalpingectomy blood loss (cm 3 ) | 9 (2 – 15) |
Table 2 Clinical indications for surgery (%). Surgical indications were mainly related to symptomatic leiomyomas in 50% followed by menorrhagia in 27% of the population. None of the patients had a history of gynecologic cancer (n = 100).
| Symptomatic leiomyomas | 50 (50%) |
| Menorrhagia | 27 (27%) |
| Uterine prolapse | 11 (11%) |
| Pelvic pain | 5 (5%) |
| Clinically benign ovarian cyst | 4 (4%) |
| Cervical dysplasia | 3 (3%) |
Table 3 Main pathologic diagnosis in uterus (n = 100) and ovary (n = 36). Histopathological analysis was always benign.
| In uterus | 100 |
adenomyosis | 30 (30%) |
benign leiomyomas | 50 (50%) |
benign mucosal polyps | 10 (10%) |
benign endometrial hyperplasia | 1 (1%) |
chronic endometritis | 1 (1%) |
| In ovary | 36 |
no pathologic abnormality | 26 (72.2%) |
functional cysts | 7 (19.4%) |
benign dermoid cyst | 1 (2.7%) |
benign serous cystadenoma | 1 (2.7%) |
benign ovarian adenofibroma | 1 (2.7%) |
Fig. 1p53 signature, hematoxylin phloxine saffron, original magnification × 400.
Fig. 2p53 signature, immunohistochemistry, original magnification × 400.
Table 4 Main pathologic diagnosis in fallopian tubes (n = 199). There were 11 tubes with the p53 signature in 9 patients, indicating a prevalence of 5.52% (11/199) with the following distribution: 7 (3.57%) unilateral p53 signatures and 2 (1%) bilateral p53 signatures. No STIC and no associated cancer were observed.
| STIC | 0 |
| p53 signatures | 11 (5.52%) |
unilateral p53 signatures | 2 (1%) |
bilateral p53 signatures | 7 (3.57%) |
| No pathologic abnormality | 179 (89.9%) |
| Benign paratubal cysts | 5 (2.5%) |
| Benign tubal papilloma | 1 (0.5%) |
| Hydrosalpinx | 1 (0.5%) |
| Benign tubal endometriosis | 1 (0.5%) |
| Benign paratubal hemangioma | 1 (0.5%) |